Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women

How does chemoendocrine therapy (CET) compared to endocrine therapy (ET) alone affect cancer-related cognitive impairment (CRCI) in pre- and postmenopausal patients?This secondary analysis of the RxPONDER randomized clinical trial included 568 participants assessed at 6, 12, and 36 months and found that CET had a greater negative association with patient-reported cognitive function compared to ET alone in both the pre- and postmenopausal groups.These findings indicate that cognitive impairment occurs and persists more frequently with CET than with ET alone among both pre- and postmenopausal patients; therefore, interventions to prevent and treat CRCI are needed.

Corresponding Author: Irene M. Kang, MD, City of Hope Comprehensive Cancer Center, 1000 Fivepoint, Irvine, CA 92618 (ikang@coh.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.